Dataset for Mathematical Model of in vitro Hepatocellular Cholesterol and Lipoprotein Metabolism, fig. 7

A comparison of therapies with anti-PCSK9 antibodies and small-molecule inhibitors. Due to higher association rate and lower dissociation rate, application of the inhibitory molecules (red curve, set 1) at the same concentration as antibodies (blue curve, set 2) leads to a faster and stronger decrease in the LDL level.

抗PCSK9抗体（anti-PCSK9 antibodies）疗法与小分子抑制剂疗法的对比分析。鉴于此类抑制性分子具备更高的结合速率与更低的解离速率，当以与抗体（蓝色曲线，组2）相同的浓度应用抑制性分子（红色曲线，组1）时，可使低密度脂蛋白（LDL，low-density lipoprotein）水平呈现更快且更显著的降低。